26 November 2021 - The agenda for the March 2022 PBAC agenda has been revised within 48 hours of publication.

Version 2.0 has five clearly marked changes:

• Pembrolizumab – clarification of submission purpose (endometrial cancer)
• Semaglutide – correction of strengths
• Bevacizumab – correction of sponsor (as we noted)
• Abemaciclib – new agenda item
• Palbociclib – addition ‘of’ in submission purpose

Read PBAC agenda